Please assess the completion status of the following clinical trial:

Trial Title: Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent grade 3 or 4 glioma, including astrocytoma, oligodendroglioma or mixed glioma with histologic confirmation at initial diagnosis or recurrence~* Candidate for gross total or subtotal resection~* Absolute neutrophil count (ANC) \>= 1500/uL~* Platelets (PLT) \>= 100,000/uL~* Total bilirubin =\< 1.5 x upper normal limit (ULN)~* Aspartate aminotransferase (AST) =\< 2 x ULN~* Creatinine =\< 2.0 x ULN~* Hemoglobin (Hgb) \>= 9.0 gm/dL~* Prothrombin time (PT) and activated partial thromboplastin time (aPTT) =\< 1.3 x ULN~* Ability to provide informed consent~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2~* Anti-measles virus immunity as demonstrated by immunoglobulin G (IgG) anti-measles antibody levels of \>= 1.1 EU/ml as determined by enzyme immunoassay~* Normal serum CEA levels (\< 3 ng/ml) at the time of registration~* Willing to provide biologic specimens as required by the protocol~* Negative serum pregnancy test done =\< 7 days prior to registration (for women of childbearing potential only)~Exclusion Criteria:~* Any of the following:~  * Pregnant women~ * Nursing women~ * Men or women of childbearing potential who are unwilling to employ adequate contraception~* Active infection =\< 5 days prior to registration~* History of tuberculosis or history of purified protein derivative (PPD) positivity~* Any of the following therapies:~  * Chemotherapy =\< 4 weeks prior to registration (6 wks for nitrosourea-based chemotherapy)~ * Immunotherapy =\< 4 weeks prior to registration~ * Biologic therapy =\< 4 weeks prior to registration~ * Bevacizumab =\< 12 weeks prior to registration~ * Non-cytotoxic antitumor drugs, i.e., small molecule cell cycle inhibitors =\< 2 weeks prior to registration~ * Radiation therapy =\< 6 weeks prior to registration~ * Any viral or gene therapy prior to registration~* Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment~* New York Heart Association classification III or IV~* Requiring blood product support~* Inadequate seizure control~* Expected communication between ventricles and resection cavity as a result of surgery~* Human immunodeficiency virus (HIV)-positive test result, or history of other immunodeficiency~* History of organ transplantation~* History of chronic hepatitis B or C~* Other concurrent chemotherapy, immunotherapy, radiotherapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration \[FDA\]-approved indication and in the context of a research investigation)~* Exposure to household contacts =\< 15 months old or household contact with known immunodeficiency~* Allergy to measles vaccine or history of severe reaction to prior measles vaccination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (resection cavity administration) (Type: EXPERIMENTAL): Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by MV-CEA administered into the resection cavity.
- Arm B (intratumoral and resection cavity administration) (Type: EXPERIMENTAL): Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA IT through the catheter over 10 minutes on day 1. Patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.

Based on this trial design, predict the completion outcome and termination type (if applicable).